Stock of the Day for December 25, 2024

Bristol Myers Squibb Stock Report

Bristol Myers Squibb
BMY 90-day performance NYSE:BMY Bristol Myers Squibb
Current Price
$43.37
-2.61 (-5.67%)
(As of 03:59 PM ET)
30 Day Performance
-8.67%
  
  
90 Day Performance
-14.22%
  
  
1 Year Performance
-8.81%
  
  
Market Capitalization
$88.27B
P/E Ratio
16.24
Dividend Yield
5.72%
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

BMY Company Calendar

JUL. 3, 2025
Ex-Dividend for 8/1 Dividend
JUL. 31, 2025
Today
JUL. 31, 2025
Last Earnings
JUL. 31, 2025
Next Earnings (Estimated)
AUG. 1, 2025
Dividend Payable
DEC. 31, 2025
Fiscal Year End

Recent Bristol Myers Squibb News

Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript
Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today
Bristol-Myers Squibb (BMY) Raises Revenue Forecast Despite EPS Cut
Bristol-Myers Squibb (BMY) Surpasses Q2 Earnings Expectations
This report was written on July 31, 2025. This report first appeared on MarketBeat.com.